

John P Bilezikian

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3147245/john-p-bilezikian-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

299
papers

26,369
citations

84
h-index

158
g-index

335
ext. papers

32,096
ext. citations

7.9
avg, IF

7.24
L-index

#	Paper	IF	Citations
299	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020 , 26, 1017-1032	50.5	1253
298	The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 2003 , 349, 1207-15	59.2	991
297	Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , 2021 , 27, 601-615	50.5	976
296	Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2990-3011	5.6	830
295	Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3561-9	5.6	778
294	A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. <i>New England Journal of Medicine</i> , 1999 , 341, 1249-55	59.2	719
293	Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 335-9	5.6	660
292	Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. <i>New England Journal of Medicine</i> , 1998 , 339, 599-603	59.2	530
291	Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 1846-53	6.3	495
290	Mechanisms of anabolic therapies for osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 357, 905-16	59.2	490
289	One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. <i>New England Journal of Medicine</i> , 2005 , 353, 555-65	59.2	477
288	Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 5353-61	5.6	462
287	Trabecular bone score: a noninvasive analytical method based upon the DXA image. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 518-30	6.3	456
286	Skeletal disease in primary hyperparathyroidism. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 283-91	6.3	425
285	The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3462-70	5.6	401
284	Osteoporosis in men: an Endocrine Society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1802-22	5.6	370
283	Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2317-37	6.3	369

282	Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 135-41	5.6	349
281	Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 75-91	3.5	344
280	Skeletal and Extraskelatal Actions of Vitamin D: Current Evidence and Outstanding Questions. <i>Endocrine Reviews</i> , 2019 , 40, 1109-1151	27.2	304
279	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 157-66	5.6	290
278	Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3069-76	5.6	280
277	The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 930-8	5.6	280
276	Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3114-21	5.6	271
275	Clinical practice. Asymptomatic primary hyperparathyroidism. <i>New England Journal of Medicine</i> , 2004 , 350, 1746-51	59.2	269
274	Glucocorticoid-induced osteoporosis: an update. <i>Trends in Endocrinology and Metabolism</i> , 2006 , 17, 144-8.8		260
273	Parathyroid hormone: anabolic and catabolic actions on the skeleton. <i>Current Opinion in Pharmacology</i> , 2015 , 22, 41-50	5.1	251
272	Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3580-94	5.6	227
271	Management of acute hypercalcemia. <i>New England Journal of Medicine</i> , 1992 , 326, 1196-203	59.2	227
270	Hyperparathyroidism. <i>Lancet, The</i> , 2018 , 391, 168-178	40	224
269	The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. <i>New England Journal of Medicine</i> , 1984 , 310, 1221-5	59.2	223
268	Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1150-6	5.6	212
267	Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. <i>Cell Metabolism</i> , 2017 , 25, 661-672	24.6	208
266	Management of Hypoparathyroidism: Summary Statement and Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2273-83	5.6	207
265	Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3319-25	5.6	204

264	The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5644-9	5.6	193
263	Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 447-56	8.1	187
262	The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. <i>American Journal of Medicine</i> , 1999 , 107, 561-7	2.4	187
261	Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 275-83	18.1	181
260	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 44-51	5.6	176
259	Presentation of Hypoparathyroidism: Etiologies and Clinical Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2300-12	5.6	175
258	Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3785-93	5.6	170
257	Osteoporosis in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 3431-4	5.6	170
256	Clinical review 123: Anabolic therapy for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 957-64	5.6	157
255	Insulin-like growth factor-I in men with idiopathic osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2799-805	5.6	150
254	Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2284-99	5.6	148
253	Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 4033-41	5.6	148
252	"Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5348-52	5.6	144
251	MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. <i>European Journal of Endocrinology</i> , 2020 , 183, R133-R147	6.5	143
250	Aromatase activity and bone homeostasis in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5898-907	5.6	142
249	Dynamic and structural properties of the skeleton in hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 2018-24	6.3	141
248	The effect of PTH(1-84) on quality of life in hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2356-61	5.6	138
247	The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. <i>Osteoporosis International</i> , 2004 , 15, 992-7	5.3	138

246	Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 1083-8	5.6	135
245	Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2306-12	5.6	134
244	High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 746-56	6.3	134
243	Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1029-40	6.3	133
242	Parathyroid carcinoma. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 1869-80	6.3	125
241	Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2194-2207	3.8	120
240	Differing effects of denosumab and alendronate on cortical and trabecular bone. <i>Bone</i> , 2014 , 59, 173-9	4.7	118
239	Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. <i>American Journal of Medicine</i> , 2009 , 122, S14-21	2.4	117
238	Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3993-4004	5.6	117
237	Primary hyperparathyroidism. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16033	51.1	113
236	Normocalcemic primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 33-9	3.5	112
235	Arterial stiffness in mild primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3326-30	5.6	112
234	Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2766-72	5.6	111
233	Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 913-9	6.3	110
232	Safety of osteoanabolic therapy: a decade of experience. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 2419-28	6.3	109
231	PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2727-36	6.3	104
230	Management of Hypoparathyroidism: Present and Future. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2313-24	5.6	103
229	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 1393-9	6.3	103

228	The use of parathyroid hormone in the treatment of osteoporosis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2006 , 7, 113-21	10.5	102
227	Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 137-44	5.6	101
226	Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17055	51.1	100
225	Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. <i>American Journal of Medicine</i> , 1989 , 87, 553-7	2.4	98
224	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVEExtend Trial. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 200-210	6.4	96
223	Utility of the trabecular bone score (TBS) in secondary osteoporosis. <i>Endocrine</i> , 2014 , 47, 435-48	4	96
222	ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2949-2957	5.6	90
221	Parathyroid hormone and the cardiovascular system. <i>Current Osteoporosis Reports</i> , 2008 , 6, 77-83	5.4	90
220	Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1309-15	5.6	89
219	Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2734-41	5.6	88
218	Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. <i>Current Osteoporosis Reports</i> , 2008 , 6, 24-30	5.4	87
217	Bone disease in primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014 , 58, 553-61		84
216	The anabolic effects of parathyroid hormone therapy. <i>Clinics in Geriatric Medicine</i> , 2003 , 19, 415-32	3.8	81
215	PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3694-9	5.6	79
214	Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1519-28	5.6	79
213	Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4725-30	5.6	76
212	Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2742-50	5.6	75
211	Osteoporosis in men. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007 , 36, 399-419	5.5	74

210	Normocalcemic primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010 , 54, 106-9		74
209	An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. <i>Clinical Chemistry</i> , 2007 , 53, 1470-6	5.5	73
208	Better skeletal microstructure confers greater mechanical advantages in Chinese-American women versus white women. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1783-92	6.3	71
207	Three dimensional cancellous bone structure in hypoparathyroidism. <i>Bone</i> , 2010 , 46, 190-5	4.7	71
206	The cell biology of parathyroid hormone in osteoblasts. <i>Current Osteoporosis Reports</i> , 2008 , 6, 72-6	5.4	67
205	Hypocalcemic Emergencies. <i>Endocrinology and Metabolism Clinics of North America</i> , 1993 , 22, 363-375	5.5	67
204	Asymptomatic primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 14-21	3.5	65
203	Parathyroid hormone as an anabolic skeletal therapy. <i>Drugs</i> , 2005 , 65, 2481-98	12.1	64
202	New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 717-23	6.3	63
201	Circulating sclerostin in disorders of parathyroid gland function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3804-10	5.6	61
200	Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. <i>Endocrinology</i> , 2008 , 149, 5713-23	4.8	60
199	Endothelial cells contain beta adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1984 , 325, 310-3	3.4	60
198	Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism. <i>Radiology</i> , 2019 , 291, 469-476	20.5	59
197	The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. <i>Journal of Bone and Mineral Research</i> , 1986 , 1, 383-8	6.3	59
196	Pharmacology of bisphosphonates. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1052-1062	3.8	59
195	New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. <i>Bone</i> , 2013 , 55, 57-63	4.7	58
194	Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. <i>European Journal of Endocrinology</i> , 2005 , 152, 199-205	6.5	57
193	Trabecular bone score is associated with volumetric bone density and microarchitecture as assessed by central QCT and HRpQCT in Chinese American and white women. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 554-61	3.5	56

192	Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up study. <i>American Journal of Medicine</i> , 2004 , 117, 169-74	2.4	56
191	Sclerostin: therapeutic horizons based upon its actions. <i>Current Osteoporosis Reports</i> , 2012 , 10, 64-72	5.4	55
190	Combination therapy with risedronate and teriparatide in male osteoporosis. <i>Endocrine</i> , 2013 , 44, 237-46	4	53
189	Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. <i>Bone</i> , 2011 , 48, 557-61	4.7	53
188	Romosozumab for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 255-263	4	52
187	Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 732-5	5.6	52
186	Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2576-9	5.6	52
185	Controversies in Vitamin D: A Statement From the Third International Conference. <i>JBMR Plus</i> , 2020 , 4, e10417	3.9	51
184	Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3535-41	5.6	50
183	Clinical spectrum of primary hyperparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2000 , 1, 237-45	10.5	50
182	New anabolic therapies in osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003 , 32, 285-307	5.5	49
181	Bone Densitometry: The Best Way to Detect Osteoporosis and to Monitor Therapy		49
180	Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 308-16	6.3	48
179	Primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018 , 32, 593-607	6.5	46
178	Optimal dietary calcium intake in primary hyperparathyroidism. <i>American Journal of Medicine</i> , 1997 , 102, 543-50	2.4	45
177	Vitamin A toxicity and hypercalcemia. <i>American Journal of the Medical Sciences</i> , 1982 , 283, 161-4	2.2	45
176	Diagnosis and management of primary hyperparathyroidism--a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2013 , 57, 406-24		42
175	Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. <i>European Journal of Endocrinology</i> , 2015 , 172, 527-35	6.5	41

174	Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 722-731	5.6	39
173	Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism. <i>Endocrine</i> , 2017 , 58, 380-385	4	38
172	Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010 , 54, 220-6		38
171	Alendronate therapy in men with primary hyperparathyroidism. <i>Endocrine Practice</i> , 2009 , 15, 705-13	3.2	38
170	Positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are associated with increases in the current, I(f), and the slope of the pacemaker potential. <i>Circulation</i> , 1997 , 96, 3704-9	16.7	38
169	Trabecular bone score: perspectives of an imaging technology coming of age. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014 , 58, 493-503		37
168	Primary Hyperparathyroidism. <i>F1000Research</i> , 2016 , 5,	3.6	37
167	Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. <i>Endocrine</i> , 2017 , 55, 591-598	4	35
166	Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	35
165	Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. <i>Journal of Bone and Mineral Research</i> , 2002 , 17 Suppl 2, N2-11	6.3	35
164	New approaches to the treatment of osteoporosis. <i>Annual Review of Medicine</i> , 2011 , 62, 307-22	17.4	34
163	Stimulation of inositol phosphate formation in ROS 17/2.8 cell membranes by guanine nucleotide, calcium, and parathyroid hormone. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 413-20	6.3	34
162	Bone strength in primary hyperparathyroidism. <i>Osteoporosis International</i> , 2003 , 14 Suppl 5, S113-5; discussion S115-7	5.3	34
161	Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 196-205	5.6	33
160	Management of normocalcemic primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018 , 32, 837-845	6.5	33
159	Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. <i>Endocrine</i> , 2017 , 55, 273-282	4	32
158	Primary hyperparathyroidism. <i>Endocrine Practice</i> , 2012 , 18, 781-90	3.2	30
157	Effect of renal function on skeletal health in primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1501-7	5.6	29

156	Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. <i>Bone Research</i> , 2013 , 1, 162-9	13.3	29
155	Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5601-5610	5.6	28
154	Bone turnover markers in primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 22-7	3.5	28
153	Asymptomatic primary hyperparathyroidism: a medical perspective. <i>Surgical Clinics of North America</i> , 2004 , 84, 787-801	4	27
152	Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 681-9	5.5	27
151	Update on romosozumab : a humanized monoclonal antibody to sclerostin. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 697-707	5.4	26
150	Stress Fractures: Concepts and Therapeutics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 525-534	5.6	26
149	Initiation of dapagliflozin and treatment-emergent fractures. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1070-1074	6.7	26
148	Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2748-2756	5.6	25
147	Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies. <i>Journal of Biomechanics</i> , 2012 , 45, 2411-6	2.9	25
146	More bone density testing is needed, not less. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 739-42	6.3	25
145	Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 252-267	3.8	24
144	Mini-review: new therapeutic options in hypoparathyroidism. <i>Endocrine</i> , 2012 , 41, 410-4	4	24
143	The official positions of the International Society for Clinical Densitometry: perceptions and commentary. <i>Journal of Clinical Densitometry</i> , 2009 , 12, 267-71	3.5	24
142	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5136-5147	5.6	23
141	AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. <i>Head and Neck</i> , 2018 , 40, 1617-1629	4.2	22
140	Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 942-7	5.6	22
139	Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	22

138	Signs and Symptoms of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 759-770	5.5	22
137	Parathyroid hormone therapy for hypoparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015 , 29, 47-55	6.5	21
136	Bone markers and osteoporosis therapy. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014 , 58, 504-13		21
135	A radioreceptor assay for propranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1979 , 26, 173-80	6.1	21
134	PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 180-9	6.3	21
133	Novel Therapies for Postmenopausal Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017 , 46, 207-219	5.5	20
132	Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1512-1521	5.6	20
131	Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4736-43	5.6	20
130	Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3484-9	5.6	20
129	Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. <i>Current Osteoporosis Reports</i> , 2006 , 4, 5-13	5.4	20
128	Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007 , 51, 1404-12		20
127	Tc99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5138-41	5.6	20
126	The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1931-1939	6.3	20
125	Primary hyperparathyroidism: recent advances. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 427-439	5.3	17
124	Combination anabolic and antiresorptive therapy for osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012 , 41, 643-54	5.5	17
123	Parathyroid hormone stimulates formation of inositol phosphates in a membrane preparation of canine renal cortical tubular cells. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 299-306	6.3	17
122	Therapy of osteoporosis in men with teriparatide. <i>Journal of Osteoporosis</i> , 2011 , 2011, 463675	2.8	16
121	Asymptomatic primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2006 , 50, 647-56		16

120	Osteoanabolic and dual action drugs. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1084-1094	3.8	16
119	Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. <i>Endocrine</i> , 2021 , 71, 267-269		16
118	PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. <i>Expert Review of Endocrinology and Metabolism</i> , 2015 , 10, 5-13	4.1	15
117	New and developing pharmacotherapy for osteoporosis in men. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 253-264	4	15
116	Idiopathic osteoporosis in men. <i>Current Osteoporosis Reports</i> , 2013 , 11, 286-98	5.4	15
115	Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4285-90	5.6	15
114	Sclerostin measurement in human disease: Validity and current limitations. <i>Bone</i> , 2017 , 96, 24-28	4.7	15
113	Modifications of the adenylate cyclase complex during differentiation of cultured myoblasts. <i>Journal of Cellular Physiology</i> , 1986 , 127, 28-38	7	14
112	Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
111	A radioreceptor assay for propranolol and 4-hydroxypropranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 28, 32-9	6.1	13
110	Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1082-8	6.3	13
109	Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future. <i>Journal of Bone and Mineral Research</i> , 2002 , 17 Suppl 2, N57-67	6.3	13
108	Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25- μ g or 50- μ g Daily Doses. <i>Clinical Therapeutics</i> , 2017 , 39, 2096-2102	3.5	12
107	Vitamin D supplementation and musculoskeletal health. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 85-86	18.1	12
106	Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. <i>Current Medical Research and Opinion</i> , 2019 , 35, 2097-2102	2.5	11
105	Infection of L6E9 myoblasts with <i>Trypanosoma cruzi</i> alters adenylate cyclase activity and guanine nucleotide binding proteins. <i>Journal of Cellular Physiology</i> , 1987 , 133, 64-71	7	11
104	Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. <i>Osteoporosis and Bone Diseases</i> , 2018 , 21, 17-22	0.8	11
103	Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 2132-2139	6.3	10

102	Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines. <i>Endocrine Practice</i> , 2009 , 15, 494-8	3.2	10
101	BEYOND DXA: ADVANCES IN CLINICAL APPLICATIONS OF NEW BONE IMAGING TECHNOLOGY. <i>Endocrine Practice</i> , 2016 , 22, 990-8	3.2	10
100	Three generational phenotypes of sporadic primary hyperparathyroidism: evolution defined by technology. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 745-747	18.1	9
99	Parathyroid hormone in the evaluation of hypercalcemia. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2680-1	27.4	9
98	Hypoparathyroidism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 1997 , 4, 427-432		9
97	Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	9
96	Osteoporosis update from the 2010 santa fe bone symposium. <i>Journal of Clinical Densitometry</i> , 2011 , 14, 1-21	3.5	8
95	Racial differences in bone density and fracture risk in the United States. <i>International Journal of Rheumatic Diseases</i> , 2008 , 11, 341-346	2.3	8
94	Osteoporosis in men: pathophysiology and treatment. <i>Current Rheumatology Reports</i> , 2007 , 9, 71-7	4.9	8
93	Total and free propranolol levels in sensitive and resistant patients. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 163-71	6.1	8
92	Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial. <i>Archives of Endocrinology and Metabolism</i> , 2016 , 60, 54-9	2.2	8
91	Primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018 , 101247	6.5	8
90	Rare Causes of Hypercalcemia: 2021 Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 3113-3128	5.6	8
89	The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 324-9	3.5	7
88	Hospital care for primary hyperparathyroidism in Italy: a 6-year register-based study. <i>European Journal of Endocrinology</i> , 2014 , 171, 481-7	6.5	7
87	New Directions in Treatment of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 901-915	5.5	7
86	How Long to Treat with Denosumab. <i>Current Osteoporosis Reports</i> , 2015 , 13, 415-20	5.4	6
85	Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1-84) Therapy in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1274-1281	6.3	6

84	Pre-operative localization of abnormal parathyroid tissue by Tc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency. <i>Endocrine</i> , 2018 , 60, 36-45	4	6
83	Stop the war on DXA!. <i>Annals of the New York Academy of Sciences</i> , 2018 , 1433, 12-17	6.5	6
82	Precision of Digital Topological Skeletonization Based Individual Trabecula Segmentation (ITS) Analysis of Trabecular Microstructure at the Distal Radius and Tibia by HR-pQCT. <i>Pattern Recognition Letters</i> , 2016 , 76, 83-89	4.7	6
81	Bone density testing: science, the media, and patient care. <i>Current Osteoporosis Reports</i> , 2014 , 12, 227-9	5.4	6
80	Teriparatide: Variations on the theme of a 2-year therapeutic course. <i>IBMS BoneKEy</i> , 2010 , 7, 84-87		6
79	2009 Santa Fe Bone symposium. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 1-9	3.5	6
78	Intracellular Ca ²⁺ homeostasis in trypomastigotes of <i>Trypanosoma cruzi</i> . <i>Journal of Eukaryotic Microbiology</i> , 1998 , 45, 80-6	3.6	6
77	Anabolic therapy for osteoporosis. <i>Women's Health</i> , 2007 , 3, 243-53	3	6
76	Update on hypoparathyroidism. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 381-387	5.3	6
75	Osteoblasts 2018 , 31-37		6
74	Bone Histomorphometry and Bone Quality in Primary Hyperparathyroidism 2015 , 429-445		5
73	Normocalcemic PHPT 2015 , 331-339		5
72	New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. <i>Bone Research</i> , 2014 , 2, 14043	13.3	5
71	Osteoporosis in men: pathophysiology and treatment. <i>Current Osteoporosis Reports</i> , 2007 , 5, 22-8	5.4	5
70	Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. <i>Expert Review of Endocrinology and Metabolism</i> , 2006 , 1, 281-295	4.1	5
69	Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 1	10.5	5
68	Clinical Presentation of Hypoparathyroidism. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab003	0.4	5
67	Anabolic therapy for osteoporosis. <i>International Journal of Fertility and Women's Medicine</i> , 2005 , 50, 53-60		5

66	Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 1201	10.5	5
65	Parathyroid hormone 1-84 alters circulating vascular endothelial growth factor levels in hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E2025-8	5.6	4
64	Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. <i>Journal of Drug Assessment</i> , 2012 , 1, 11-9	1.5	4
63	Osteoporosis: what's new and on the horizon. <i>Clinical Obstetrics and Gynecology</i> , 2013 , 56, 730-8	1.7	4
62	A Simple Formula to Estimate Parathyroid Weight on 4D-CT, Predict Pathologic Weight, and Diagnose Parathyroid Adenoma in Patients with Primary Hyperparathyroidism. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1690-1697	4.4	4
61	Report on the Audit on Burden of Osteoporosis in Eight Countries of the Eurasian Region: Armenia, Belarus, Georgia, Moldova, Kazakhstan, the Kyrgyz Republic, the Russian Federation, and Uzbekistan. <i>Archives of Osteoporosis</i> , 2020 , 15, 175	2.9	3
60	Osteoporosis update from the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 584-600	3.5	3
59	Skeletal Imaging in Primary Hyperparathyroidism 2015 , 447-454		3
58	Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?. <i>Archives of Endocrinology and Metabolism</i> , 2020 , 64, 331-336	2.2	3
57	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1861-1872	2.5	3
56	Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 297-316	10.5	3
55	Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1303-1311	5.6	3
54	The Epidemiology of Osteoporotic Fractures 2018 , 398-404		3
53	Asymptomatic Primary Hyperparathyroidism 2015 , 317-330		2
52	Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
51	Hypoglycemia Secondary to Sulfonylurea Ingestion in a Patient with End Stage Renal Disease: Results from a 72-Hour Fast. <i>Case Reports in Endocrinology</i> , 2015 , 2015, 742781	1.2	2
50	DXA-Based Bone Strain Index: A New Tool to Evaluate Bone Quality in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2304-2312	5.6	2
49	Bone Mineral Density: Clinical Relevance and Quantitative Assessment. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 446-454	8.9	2

48	Hypocalcemia 2018 , 646-653		2
47	Bone Turnover Markers in Primary Hyperparathyroidism 2015 , 423-428		1
46	Anabolic and Catabolic Pathways of Parathyroid Hormone on the Skeleton 2015 , 233-244		1
45	Skeletal Manifestations of Hypoparathyroidism 2015 , 771-779		1
44	Non-surgical management of primary hyperparathyroidism in the aging population. <i>Maturitas</i> , 2020 , 136, 49-53	5	1
43	Primary hyperparathyroidism [Hypercalcemic and normocalcemic variants. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018 , 3, 42-50	1.7	1
42	Trabecular bone score: a useful clinical tool for the evaluation of skeletal health in women of short stature. <i>Endocrine</i> , 2019 , 66, 398-404	4	1
41	Spontaneous Remission of Primary Hyperparathyroidism Related to an Autoimmune Disease: A Case Report. <i>AACE Clinical Case Reports</i> , 2015 , 1, e255-e259	0.7	1
40	Lawrence G. Raisz November 13, 1925-August 25, 2010. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 903-11	6.3	1
39	Enhancement of parathyroid hormone-responsive renal cortical adenylate cyclase activity by a cytosol protein activator from rat reticulocytes. <i>Journal of Bone and Mineral Research</i> , 1986 , 1, 41-50	6.3	1
38	Reticulocyte cytosol activator protein: its actions upon the beta adrenergic receptor and the N-proteins of adenylate cyclase. <i>Journal of Receptors and Signal Transduction</i> , 1984 , 4, 475-86		1
37	The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022 , 1	10.5	1
36	Osteitis Fibrosa Cystica. <i>JBMR Plus</i> , 2020 , 4, e10403	3.9	1
35	Bone Quality as Measured by Trabecular Bone Score in Normocalcemic Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2021 , 27, 992-997	3.2	1
34	Association between fibroblast growth factor 23 and functional capacity among independent elderly individuals. <i>Einstein (Sao Paulo, Brazil)</i> , 2021 , 19, eAO5925	1.2	1
33	Primary Hyperparathyroidism: Pathophysiology, Surgical Indications, and Preoperative Workup 2021 , 486-493.e2		1
32	Clinical phenotypes of primary hyperparathyroidism in hospitalized patients who underwent parathyroidectomy. <i>Endocrine Connections</i> , 2021 , 10, 248-255	3.5	1
31	Trabecular Bone Score 2018 , 277-286		1

30	Chapter 66. Primary Hyperparathyroidism 301-306		1
29	Osteoporosis in Men 2014 , 323-333		1
28	Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1900-1901	6.3	0
27	Pharmacologic mechanisms of therapeutics 2020 , 1633-1642		0
26	Biochemical Markers of Bone Turnover in Osteoporosis 2018 , 293-301		0
25	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism 2015 , 489-497		
24	Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production. <i>Endocrine</i> , 2018 , 60, 524-527		4
23	New Approaches to Osteoporosis Therapeutics 2013 , 1963-1985		
22	The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism and in Osteoporosis 2013 , 1249-1265		
21	Effects of guanine nucleotides and parathyroid hormone on inositol 1,4,5-trisphosphate metabolism in canine renal cortical tubular cell membranes. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 599-607	6.3	
20	Osteoporosis in men: Pathophysiology and treatment. <i>Current Sexual Health Reports</i> , 2008 , 5, 83-89	1.2	
19	Release of guanosine triphosphate binding protein β subunits from mouse myocardial membranes: Basic properties and their alterations in acute murine Chagas disease. <i>Cardiovascular Research</i> , 1995 , 29, 350-358	9.9	
18	Treatment with Parathyroid Hormone 2020 , 25-31		
17	PTH and PTHrP Analogs: Treatment of Osteoporosis. <i>Contemporary Endocrinology</i> , 2020 , 349-362		0.3
16	Primary hyperparathyroidism: Rheumatologic manifestations and bone disease 2015 , 1688-1691		
15	Replacement Therapy with PTH(184) 2015 , 333-342		
14	Primary Hyperparathyroidism; Current Management Guidelines 2017 , 331-341		
13	Primary Hyperparathyroidism in Men 2010 , 465-478		

12 Approach to Parathyroid Disorders 535-542

11 Combination Anabolic and Antiresorptive Therapy for Osteoporosis 444-447

10 Clinical and translational pharmacology of bisphosphonates **2020**, 1671-1687

9 Drugs acting on the calcium receptor **2020**, 1657-1670

8 Bone quality in hypoparathyroidism. *Minerva Endocrinology*, **2021**, 46, 325-334

2.5

7 The skeletal actions of parathyroid hormone in primary hyperparathyroidism **2021**, 1159-1173

6 Sarcopenia and Osteoporosis **2018**, 498-504

5 Adverse Effects of Drugs for Osteoporosis **2018**, 579-587

4 Hypocalcemic Crisis: Acute Postoperative and Long-Term Management of Hypocalcemia **2022**, 113-124

3 When should a gynecologist refer a patient for specialty care in osteoporosis?. *International Journal of Fertility and Women's Medicine*, **2003**, 48, 132-6; discussion 137-8

2 Osteoporosis in Men **2022**, 273-284

1 Hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism in a developed country in the Asia Pacific. A cohort study.. *Osteoporosis and Sarcopenia*, **2022**, 8, 11-16

2.3